×
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
LON:DDDD

4D pharma Share Forecast, Price & News

GBX 16.66
+0.80 (+5.04%)
(As of 06/24/2022)
Add
Compare
Today's Range
15.28
16.86
50-Day Range
15.20
45.25
52-Week Range
13.60
108.60
Volume
912,370 shs
Average Volume
2.96 million shs
Market Capitalization
£30.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive DDDD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter.

DDDD Stock Forecast (MarketRank)

Overall MarketRank

1.08 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
4D pharma logo

About 4D pharma (LON:DDDD)

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

DDDD Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
106
Year Founded
N/A

Company Calendar

Last Earnings
9/30/2020
Today
6/29/2022
Next Earnings (Estimated)
9/28/2022

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£718 thousand
Cash Flow
GBX 11.60 per share
Book Value
GBX 18 per share

Miscellaneous

Free Float
N/A
Market Cap
£30.04 million
Optionable
Not Optionable
Beta
N/A














4D pharma Frequently Asked Questions

How has 4D pharma's stock performed in 2022?

4D pharma's stock was trading at GBX 53.60 on January 1st, 2022. Since then, DDDD shares have decreased by 68.9% and is now trading at GBX 16.66.
View the best growth stocks for 2022 here
.

When is 4D pharma's next earnings date?

4D pharma is scheduled to release its next quarterly earnings announcement on Wednesday, September 28th 2022.
View our earnings forecast for 4D pharma
.

How were 4D pharma's earnings last quarter?

4D pharma plc (LON:DDDD) released its quarterly earnings data on Wednesday, September, 30th. The company reported ($14.06) EPS for the quarter.
View 4D pharma's earnings history
.

Who are 4D pharma's key executives?

4D pharma's management team includes the following people:
  • Mr. Duncan Joseph Peyton, CEO & Exec. Director (Age 52, Pay $254k)
  • Dr. Alexander James Stevenson Ph.D., Chief Scientific Officer & Exec. Director (Age 50, Pay $218k)
  • Mr. John Brendan Doyle, Chief Financial Officer (Age 44)
  • Ms. Fay Weston, Head of Investor Relations
  • Mr. Adrian Murray, Gen. Counsel (Interim)
  • Mr. Glenn Dourado, Exec. VP of Corp. Devel.
  • Ms. Lucy Christie, VP of HR
  • Mr. Christophe Carite, Sr. VP of CMC & Process Devel.
  • Ms. Imke Mulder, Exec. VP of Research

What other stocks do shareholders of 4D pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 4D pharma investors own include Amigo (AMGO), Adamis Pharmaceuticals (ADMP), American Airlines Group (AAL), Boeing (BA), Cineworld Group (CINE), Cray (CRAY), Omega Diagnostics Group (ODX), Oracle (ORCL), Senseonics (SENS) and Tullow Oil (TLW).

What is 4D pharma's stock symbol?

4D pharma trades on the London Stock Exchange (LON) under the ticker symbol "DDDD."

How do I buy shares of 4D pharma?

Shares of DDDD and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is 4D pharma's stock price today?

One share of DDDD stock can currently be purchased for approximately GBX 16.66.

How much money does 4D pharma make?

4D pharma (LON:DDDD) has a market capitalization of £30.04 million and generates £718 thousand in revenue each year.

How many employees does 4D pharma have?

4D pharma employs 106 workers across the globe.

How can I contact 4D pharma?

4D pharma's mailing address is 9 Bond Court, LEEDS, LS1 2JZ, United Kingdom. The official website for 4D pharma is www.4dpharmaplc.com. The company can be reached via phone at +44-113-8950130.

This page (LON:DDDD) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.